🎧 Hosts: Na-Ri Oh & Ian Wendt
🎓 Special Guests: Emma Cousin (PhD Candidate, Choice Institute – UW), Amos Fung (RealPharma Intern & Student Pharmacist)
🔍 Episode Summary:
In this thought-provoking episode, hosts Na-Ri Oh and Ian Wendt sit down with Emma Cousin, a PhD candidate at the Choice Institute, University of Washington, to unpack the real-world implications of the Inflation Reduction Act (IRA)—particularly the Medicare Drug Price Negotiation Program.
Joining them is Amos Fung, a RealPharma intern who brings a front-line pharmacy perspective to the policy conversation.
Together, they discuss:
📜 A primer on the IRA’s healthcare provisions—what it is, how it came to be, and why it matters now.
💊 How CMS selects drugs for Medicare negotiation and whether this process constitutes true “negotiation.”
👩⚕️ The ripple effects on pharmacists, pharmacies, and patient care.
💸 The looming concerns around cashflow, operational readiness, and access as the 2026 implementation date approaches.
🧠 How researchers like Emma are modeling long-term effects—and what metrics we’ll need to track to assess the IRA’s success.
🔄 Unintended consequences and who might be left behind—especially independent pharmacies and vulnerable communities.
📈 A candid discussion on myths around drug pricing and why “good intentions” in policy still need strong evidence and thoughtful execution.
🎯 Key Takeaways:
The IRA marks the first time Medicare can directly negotiate drug prices—albeit in a tightly structured format that raises questions about the fairness of “negotiation.”
Pharmacies face operational and financial strain, particularly smaller or independent ones, due to rebate lags and implementation complexities.
Patients will benefit from caps on out-of-pocket costs, but awareness and education are lacking—many don’t realize what the law offers.
Stakeholders like pharmacists, researchers, and policy influencers need better communication and clearer technical standards from CMS.
Evidence-based policy should be the north star for drug pricing reforms, but real-world implementation remains messy and evolving.
🧠 Resources & Mentions:
Brian Reid & Adam Fein – Top newsletters to follow for updates on drug pricing policy.
CMS Guidance Documents – Frequently updated, but often inaccessible to non-policy experts.
National Pharmaceutical Council, Milliman, Portal (Harvard) – Organizations doing forward-looking modeling and policy impact research.
